$USNA

FULLER GILBERT A sold $20K of USNA

FULLER GILBERT A sold 1,057 shares of USANA HEALTH SCIENCES INC (USNA) at $18.66 on 2026-05-22.

Original reporting
SEC EDGAR · FULLER GILBERT A
Published May 26, 2026, 3:37 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 26, 2026, 3:44 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$USNA
Bearish
medium confidence
Mentioned
$USNA
Relevance
7/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$USNABearishMed
01

Why it matters

Because the filing only documents an open-market sale by a director, it primarily affects short-term sentiment/positioning rather than providing new information about earnings, products, or guidance.

02

Market read

Traders may monitor for follow-on insider activity or unusual volume, but there is no fundamental catalyst in the text.

03

What to watch

No stated reason for the sale, no 10b5-1 plan disclosed, and the filing shows holdings after the trade are 0 shares—this can amplify optics without implying future performance.

Relevance 7/10Timing: Filing dated 2026-05-26; transaction executed 2026-05-22, so market impact is most relevant around the filing/after-hours attention window.

Background

The article is an SEC Form 4 insider transaction disclosure for USANA Health Sciences, reported via EDGAR.

Company-level read

Ticker impact

$USNABearishMedium confidence
Context

USANA director Fuller Gilbert A filed an open-market sale of 1,057 shares at $18.6648 on 2026-05-22, leaving 0 shares.

Expected impact

Near-term drift possible on attention/positioning, but likely limited magnitude because the sale is small and no 10b5-1 plan is cited.

Evidence & confidence

The article contains only an SEC Form 4 transaction (no earnings, guidance, or operational catalyst). Insider sales can be read as caution, yet the absence of a 10b5-1 plan does not, by itself, confirm negative fundamentals.

Market effects

Minimal; this is company-specific insider activity without broader sector signals.

None indicated.

None indicated.

Counterpoint

Insider selling to diversify personal exposure is common and the disclosed size/value is modest, so it may not reflect a bearish view on USNA fundamentals.

Key entities

  • USANA HEALTH SCIENCES INC

    Subject of the insider transaction disclosure; director Fuller Gilbert A sold 1,057 shares.

  • FULLER GILBERT A

    USANA director who executed the open-market sale and reported holdings after the transaction.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$USNAMedAI 8/10

USANA (USNA) Q2 2026 Earnings Call Transcript

USANA (USNA) held its Q2 2026 earnings call. Management said Core Nutritional was stable, with Mainland China showing renewed strength. The company recorded a preliminary $29 million noncash goodwill impairment and $9 million income tax expense on a $19 million pretax loss. USANA ended the quarter with $169 million cash, zero debt, and $20 million free cash flow, and lowered its fiscal 2026 outlook due to HYA DTC marketing and Rise net sales.

$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

$USNAHighAI 9/10

Why Usana Health Sciences Stock Plummeted This Week

Usana Health Sciences (USNA) shares fell about 30% after its Aug. 4 Q2 results missed expectations and guidance disappointed. The company reported non-GAAP EPS of $0.07 on about $223M sales, with sales and profit below analyst averages. It also took a $29M goodwill impairment on Hiya, cut 2024 guidance to an $11M loss and lowered sales to $910M from $925M-$1B.

$USNAHigh

USANA HEALTH SCIENCES INC (USNA): Results of Operations and Financial Condition

USANA HEALTH SCIENCES INC (USNA) filed an SEC Form 8-K — Results of Operations and Financial Condition. USANA Health Sciences Reports Second Quarter 2026 Results Company Continues Evolution to a Diversified, Omnichannel Health and Wellness Business SALT LAKE CITY, August 4, 2026 (BUSINESS WIRE)—USANA Health Sciences, Inc. (NYSE: USNA) today announced financial results for its fisca